These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36927160)

  • 1. A review of emerging factor XI inhibitors.
    Elsheikh S; Tidbury N; Lip GYH
    Expert Opin Emerg Drugs; 2023 Mar; 28(1):43-53. PubMed ID: 36927160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting factor XI and factor XIa to prevent thrombosis.
    Gailani D; Gruber A
    Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
    Harrington J; Piccini JP; Alexander JH; Granger CB; Patel MR
    J Am Coll Cardiol; 2023 Feb; 81(8):771-779. PubMed ID: 36813377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
    Prakash S; Mares AC; Porres-Aguilar M; Mukherjee D; Barnes GD
    Vasc Med; 2024 Feb; 29(1):85-92. PubMed ID: 37947131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the discovery and development of factor XI/XIa inhibitors.
    Al-Horani RA; Afosah DK
    Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor XIa inhibitors: A review of the patent literature.
    Al-Horani RA; Desai UR
    Expert Opin Ther Pat; 2016; 26(3):323-45. PubMed ID: 26881476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. News at XI: moving beyond factor Xa inhibitors.
    Fredenburgh JC; Weitz JI
    J Thromb Haemost; 2023 Jul; 21(7):1692-1702. PubMed ID: 37116752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of factor XIa as a new approach to anticoagulation.
    Schumacher WA; Luettgen JM; Quan ML; Seiffert DA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):388-92. PubMed ID: 20139363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of FXIa Inhibition as a Novel Target for Anticoagulation.
    Koulas I; Spyropoulos AC
    Hamostaseologie; 2023 Feb; 43(1):28-36. PubMed ID: 36807817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New anticoagulants in 2024: Development of factor XI and XIa inhibitors].
    Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
    Ann Biol Clin (Paris); 2024 Apr; 82(1):9-23. PubMed ID: 38638015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors.
    Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
    J Med Vasc; 2023 Apr; 48(2):69-80. PubMed ID: 37422330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
    Chan NC; Weitz JI
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.
    Li T; Liu J; Wu W
    Front Cardiovasc Med; 2022; 9():975767. PubMed ID: 36386334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
    Salomon O; Gailani D
    J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value for increased activated factor XI activity in acute venous thromboembolism.
    Nagy M; Robles AP; Visser M; Koeck T; Ten Cate V; Ten Cate-Hoek AJ; Schwers S; Heitmeier S; Ten Cate H; Wild PS; Spronk HMH
    J Thromb Haemost; 2023 Jun; 21(6):1610-1622. PubMed ID: 37003466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation.
    Székely O; Borgi M; Lip GYH
    Expert Opin Emerg Drugs; 2019 Mar; 24(1):55-61. PubMed ID: 30845846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XI inhibition in cardiovascular disease.
    Carlin S; Jakovac M; Budaj A; Eikelboom J
    Pol Arch Intern Med; 2024 Aug; 134(7-8):. PubMed ID: 38984712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XI: structure, function and therapeutic inhibition.
    Ali AE; Becker RC
    J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38622277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma.
    Modrzycka S; Kołt S; Adams TE; Potoczek S; Huntington JA; Kasperkiewicz P; Drąg M
    J Med Chem; 2023 Mar; 66(6):3785-3797. PubMed ID: 36898159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
    Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.